This notion aligns with the amyloid hypothesis, based on which the greatest opportunity for therapeutic impact is early in the disease process, when AD-related tau pathology is still spatially restricted to the medial temporal lobe and remains dependent on the presence of upstream Aβ pathology. Here, MAPT is linked to Alzheimer disease.